S. Detre

发表

Comparison of new immunohistochemical assay for oestrogen receptor in paraffin wax embedded breast carcinoma tissue with quantitative enzyme immunoassay.

M. Dowsett, J. Salter, S. Johnston, 1994, Journal of clinical pathology.

Immunohistochemical and biochemical analysis of the oestrogen regulated protein pS2, and its relation with oestrogen receptor and progesterone receptor in breast cancer.

K. Maclennan, M. Dowsett, J. Salter, 1994, Journal of clinical pathology.

and progesterone receptor in breast cancer . pS 2 , and its relation with oestrogen receptor analysis of the oestrogen regulated protein Immunohistochemical and biochemical

K. Maclennan, M. Dowsett, J. Salter, 2022 .

The farnesyltransferase inhibitor R 115777 ( tipifarnib ) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo

M. Dowsett, J. Salter, E. Quinn, 2007 .

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer with Acquired Endocrine Resistance

M. Dowsett, S. Johnston, A. Lykkesfeldt, 2010, Clinical Cancer Research.

Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer--a study from the IMPACT trialists.

M. Dowsett, S. Ebbs, J. Salter, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunohistochemical Phenotype of Breast Cancer during 25-Year Follow-up of the Royal Marsden Tamoxifen Prevention Trial

T. Powles, M. Dowsett, I. Smith, 2017, Cancer Prevention Research.

Cancer Therapy: Clinical Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

M. Dowsett, A. Harris, J. Salter, 2011 .

Assessment of the Spatial Heterogeneity of Breast Cancers: Associations Between Computed Tomography and Immunohistochemistry

V. Goh, M. Dowsett, A. Makris, 2019, Biomarkers in cancer.

The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer

Jeff S. Jasper, M. Dowsett, G. Crawford, 2019, Cell reports.

The use of anti-ricin antibodies to protect mice intoxicated with ricin.

B. Foxwell, P. Thorpe, S. Detre, 1985, Toxicology.

Modification of the carbohydrate in ricin with metaperiodate-cyanoborohydride mixtures. Effects on toxicity and in vivo distribution.

F. Stirpe, B. Foxwell, G. Wilson, 1985, European journal of biochemistry.

Induction of apoptosis by tamoxifen and ICI 182780 in primary breast cancer

A. Howell, M. Dowsett, P. Ellis, 1997, International journal of cancer.

M. Dowsett, J. Salter, S. Johnston, 1999, International journal of cancer.

The control and biological importance of intratumoural aromatase in breast cancer

M. Dowsett, M. Rowlands, V. Macaulay, 1996, The Journal of Steroid Biochemistry and Molecular Biology.

Influence of neoadjuvant anastrozole (Arimidex) on intratumoral estrogen levels and proliferation markers in patients with locally advanced breast cancer.

P. Lønning, M. Dowsett, L. Ottestad, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relationship between ER expression by IHC or mRNA with Ki67 response to aromatase inhibition: a POETIC study

M. Dowsett, M. Cheang, E. Mallon, 2022, Breast cancer research : BCR.

Biological Evidence for Dual Antiangiogenic-Antiaromatase Activity of the VEGFR Inhibitor PTK787/ZK222584 In vivo

M. Dowsett, R. A’Hern, D. Evans, 2010, Clinical Cancer Research.

Clinical Cancer esearch cer Therapy : Preclinical logical Evidence for Dual Antiangiogenic-Antiaromatase R ivity of the VEGFR Inhibitor PTK 787 / ZK 222584 In vivo

R. A’Hern, Lesley-Ann Martin, A. Banerjee, 2010 .

Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.

R. Schiff, M. Dowsett, D. Allred, 2005, Endocrine-related cancer.

An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells

A. Ashworth, M. Dowsett, Katherine Lee, 1995, International journal of cancer.

Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer

M. Dowsett, J. Salter, I. Smith, 2010, Breast Cancer Research.

Exon S Deletion Variant Estrogen Receptor Messenger RNA Expression in Relation to Tamoxifen Resistance and Progesterone Receptor / pS 2 Status in Human Breast Cancer '

I. Smith, Nicholas, Dowsett, 2022 .

Immunohistochemical Phenotype after 20-Year Follow-Up of the Royal Marsden Tamoxifen Breast Cancer Prevention Trial (RMTBCPT).

M. Dowsett, I. Smith, S. Ashley, 2009 .

Comparison of the selective estrogen receptor modulator arzoxifene (LY353381) with tamoxifen on tumor growth and biomarker expression in an MCF-7 human breast cancer xenograft model.

M. Dowsett, J. Salter, S. Johnston, 2003, Cancer research.

Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy

M. Dowsett, P. Ellis, J. Salter, 1998, Breast Cancer Research and Treatment.

Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer.

M. Dowsett, P. Ellis, I. Smith, 1998, Journal of clinical pathology.

breast cancer . cleavage in apoptotic cells in patients with Comparison of in situ methods to assess DNA

M. Dowsett, P. Ellis, P. Mainwaring, 1998 .

Proliferation and Apoptosis as Markers of Benefit in Neoadjuvant Endocrine Therapy of Breast Cancer

M. Dowsett, S. Ebbs, J. Salter, 2006, Clinical Cancer Research.

Short-term presurgical treatment for all?

M. Dowsett, J. Salter, I. Smith, 2007, Breast Cancer Research.

PDFlib PLOP: PDF Linearization, Optimization, Protection Page inserted by evaluation version

T. Powles, M. Dowsett, P. Ellis, 2006 .

Oncogene Products and Other Diagnostic Markers in Human Breast Cancer Patients

T. Powles, M. Dowsett, P. Ellis, 1996, Annals of the New York Academy of Sciences.

Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.

R. Schiff, M. Dowsett, D. Allred, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Cytotoxicity acquired by conjugation of an anti-Thy1.1 monoclonal antibody and the ribosome-inactivating protein, gelonin.

D. C. Edwards, F. Stirpe, P. Thorpe, 1981, European journal of biochemistry.

A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas.

S Detre, M. Dowsett, M Dowsett, 1995, Journal of clinical pathology.

Serum alpha1-foetoprotein levels in 153 male patients with germ cell tumours.

K. Grigor, A. Neville, S. Detre, 1977, British Journal of Cancer.

Transplantation of Human Tumour to Immune Deprived Mice Treated with Anti-thymocyte Serum

J. Gazet, S. Detre, 1973, British Journal of Cancer.

Embryonic transcription factor SOX9 drives breast cancer endocrine resistance

Henry W. Long, R. Schiff, C. Paweletz, 2017, Proceedings of the National Academy of Sciences.

Close and Stable Relationship between Proliferation and a Hypoxia Metagene in Aromatase Inhibitor–Treated ER-Positive Breast Cancer

M. Dowsett, A. Harris, J. Salter, 2011, Clinical Cancer Research.

Estrogen-regulated feedback loop limits the efficacy of estrogen receptor–targeted breast cancer therapy

M. Dowsett, X. Liu, Han Xu, 2018, Proceedings of the National Academy of Sciences.

Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.

Mitch Dowsett, Roger A'Hern, M. Dowsett, 2007, Journal of the National Cancer Institute.

Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials

J. Cuzick, A. Howell, T. Powles, 2016, Breast Cancer Research and Treatment.

A phase II placebo-controlled trial of neoadjuvant anastrozole alone or with gefitinib in early breast cancer.

M. Dowsett, J. Mayordomo, J. Salter, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Changes in breast cancer biomarkers in the IGF1R/PI3K pathway in recurrent breast cancer after tamoxifen treatment.

M. Dowsett, J. Reis-Filho, J. Salter, 2011, Endocrine-related cancer.

Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival.

M. Dowsett, S. Ebbs, J. Salter, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Heterogeneity in global gene expression profiles between biopsy specimens taken peri-surgically from primary ER-positive breast carcinomas

M. Dowsett, J. Parker, M. Cheang, 2016, Breast Cancer Research.

Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials

Jack Cuzick, Adam R. Brentnall, Ivana Sestak, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Monoclonal antibody therapy: "model" experiments with toxin-conjugated antibodies in mice and rats.

D. Mason, P. Thorpe, W. Ross, 1983, Haematology and blood transfusion.

Secretion of immunoreactive calcitonin by human breast carcinomas.

R. Coombes, A. Neville, S. Girgis, 1975, British medical journal.

Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R115777 in human breast cancer.

M. Dowsett, P. Workman, A. Howes, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

The farnesyltransferase inhibitor R115777 (tipifarnib) in combination with tamoxifen acts synergistically to inhibit MCF-7 breast cancer cell proliferation and cell cycle progression in vitro and in vivo

M. Dowsett, J. Salter, E. Quinn, 2007, Molecular Cancer Therapeutics.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

M. Dowsett, S. Pinder, W. Symmans, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluation of FLT-PET-CT as an imaging biomarker of proliferation in primary breast cancer

S Detre, M. Dowsett, B. Sanghera, 2014, British Journal of Cancer.

Comparative validation of the SP6 antibody to Ki67 in breast cancer

M. Dowsett, J. Salter, E. Quinn, 2010, Journal of Clinical Pathology.

Biomarkers and predictive factors of response to neoadjuvant treatment

M. Dowsett, J. Salter, A. Dunbier, 2009, Breast Cancer Research.

Evaluation of Ki-67 proliferation and apoptotic index before, during and after neoadjuvant chemotherapy for primary breast cancer

Andreas Makris, Frances Daley, Mitch Dowsett, 2006, Breast Cancer Research.

Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer.

M. Dowsett, S. Johnston, I. Smith, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.

M. Dowsett, I. Smith, S. Johnston, 1995, Cancer research.

Comparison of the growth of xenografts in various kinds of immunodeficient mice

S. Detre, 1980 .

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

M. Dowsett, S. Johnston, I. Smith, 2014, Clinical Cancer Research.

Clinico-pathologic relationships with Ki67 and its change with short-term aromatase inhibitor treatment in primary ER + breast cancer: further results from the POETIC trial (CRUK/07/015)

M. Dowsett, L. Zabaglo, E. Mallon, 2023, Breast Cancer Research.

Preoperative chemotherapy induces apoptosis in early breast cancer

M. Dowsett, P. Ellis, J. Salter, 1997, The Lancet.

Biological and clinical outcomes from a phase II placebo-controlled neoadjuvant study of anastrozole alone or with gefitinib in postmenopausal women with ER/PgR+ breast cancer (Study 223).

M. Dowsett, J. Mayordomo, J. Salter, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy.

M. Dowsett, S. Pinder, W. Symmans, 2015 .

Analysis and sorting of apoptotic cells from fine-needle aspirates of excised human primary breast carcinomas.

M. Dowsett, P. Ellis, P. Mainwaring, 1998, Cytometry.

An unusual artefact in the terminal deoxynucleotidyl transferase assay for apoptotic cells.

M. Dowsett, J. Titley, M. Ormerod, 1997, Cytometry.